Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease

Assessment of the Oxygen Use and Future Outcomes Associated With Oxygen Use in Patient With Fibrotic ILD

The purpose of this study is to describe initiation and use of oxygen therapy among patients with fibrotic Interstitial Lung Disease (ILD) and to assess the impact of oxygen therapy on clinical outcomes among patients with fibrotic ILD.

Inclusion criteria:

• ≥2 fibrosing Interstitial Lung Disease (ILD) diagnoses in any position on different dates of service, within 365 days of each other, and in the same continuous enrollment period during the patient identification period. The fibrosing ILD diagnosis date will be defined as the date of the first fibrosing ILD diagnosis. The two fibrosing ILD diagnosis codes can be one of the following combinations:
• 2 fibrosis codes
• 1 fibrosis code & 1 ILD code that requires fibrosis code
• ≥18 years of age as of the fibrosing ILD diagnosis date
• Continuous enrollment with medical and pharmacy coverage for 12 months prior to the fibrosing ILD diagnosis date (pre-ILD baseline period)

Exclusion criteria:

• Fibrosing ILD diagnosis in the 12-month pre-ILD baseline period
• Unknown gender, geographic region, or insurance type